Drug intelligence / Profile preview

SPARC-1507

Development stage: Discontinued
Lead developer: SPARC
Modality: Small Molecules

Overview

SPARC-1507 is a small molecule drug that was developed by Sun Pharma Advanced Research Company (SPARC) for the treatment of neoplasms, with a primary focus on advanced biliary tract cancer. The drug reached Phase 3 clinical development but the pivotal trial (NCT02597465) was withdrawn and the global highest R&D status is now listed as discontinued. The precise mechanism of action for SPARC-1507 has not been disclosed in public sources[1][2][3]. No regulatory approvals have been granted for this agent.

Beyond the preview

Go deeper on SPARC-1507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC-1507.

Explore the full profile